Acute exposure of cancer cells to high concentrations of type I interferon (IFN-I) drives
growth arrest and apoptosis, whereas chronic exposure to low concentrations provides …

The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence
have been recognized for many decades. Due to their strong capacity for self-renewal and …

Cancer stem cells (CSCs) are a subpopulation of cancer cells endowed with high
tumorigenic, chemoresistant and metastatic potential. Nongenetic mechanisms of acquired …

During tumorigenesis, tumors must evolve to evade the immune system and do so by
disrupting the genes involved in antigen processing and presentation or up-regulating …

Type I interferon (IFN) is a class of proinflammatory cytokines with a dual role on malignant
transformation, tumor progression, and response to therapy. On the one hand, robust, acute …

Tumor immunity represents a new avenue for cancer therapy. Immune checkpoint inhibitors
have successfully improved outcomes in several tumor types. In addition, currently, immune …

The first report on the antitumor effects of interferon α/β (IFN-I) in mice was published 50
years ago. IFN-α were the first immunotherapeutic drugs approved by the FDA for clinical …

Abstract Background Type I interferons (IFN-I) have recently emerged as key regulators of
tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T …

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer
patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of …

Introduction Intestinal immune dysregulation is strongly linked to the occurrence and
formation of tumors. RING finger protein 128 (RNF128) has been identified to play distinct …